Prostate cancer: test predicts abiraterone, enzalutamide response

  • Armstrong AJ & al.
  • J Clin Oncol
  • 13 Mar 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In men with high-risk metastatic castration-resistant prostate cancer (mCRPC), detection of androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTC) was independently associated with worse survival with abiraterone or enzalutamide.

Why this matters

  • AR-V7-positive patients should be offered alternative treatments.

Study design

  • Multicenter, prospective-blinded PROPHECY study of 118 men with high-risk mCRPC who received abiraterone acetate or enzalutamide.
  • AR-V7 detection was done by 2 blood-based Johns Hopkins University (JHU)-modified and EPIC sciences assays.
  • Funding: Prostate Cancer Foundation; Movember.

Key results

  • Median follow-up time, 19.6 months.
  • The percentage agreement between the 2 assays was 82%.
  • Presence of AR-V7 by Johns Hopkins and Epic AR-V7 assays was independently associated with shorter:
    • PFS (HR, 1.9 [P=.032] and HR, 2.4 [P=.020], respectively).
    • OS (HR, 4.2 [95% CI, 2.1-8.5] and HR, 3.5 [95% CI, 1.6-8.1], respectively).
  • No Epic AR-V7-positive patients had a confirmed PSA or RECIST response.
  • 11% and 6% of JHU AR-V7-positive patients had confirmed PSA and RECIST responses, respectively.

Limitations

  • Lack of testing with alternative treatment strategies.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit